Physician profile
Naveen Kumar
NPI 1659569911
$8,505.13
in general payments reported to CMS, 2019-2025
36 companies · $1,848 in 2025
The $1,848 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $648 · 2021: $1,458 · 2022: $1,136 · 2023: $1,395 · 2024: $1,303 · 2025: $1,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,536 · Gift: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,535.94 |
| Gift | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,784.70 | 2019-2025 | Airsupra, Fasenra, Farxiga |
| Amgen INC. | $954.35 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Novo Nordisk INC | $864.57 | 2019-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $810.92 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $556.34 | 2023-2025 | |
| Lilly USA, LLC | $359.41 | 2020-2024 | Emgality, Mounjaro, Reyvow |
| Biosense Webster, INC. | $294.67 | 2024-2025 | Nuvision Ice Catheter, Carto 3 |
| Sanofi-Aventis U.S. LLC | $266.26 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.20 | 2020-2022 | |
| Astellas Pharma US INC | $214.09 | 2019-2024 | Myrbetriq, Veozah |
| Medtronic, INC. | $202.64 | 2025 | Interstim |
| Radius Health, INC. | $176.13 | 2019-2020 | |
| Abbott Laboratories | $173.70 | 2022 | |
| Merck Sharp & Dohme LLC | $168.26 | 2021-2025 | Verquvo, Gardasil 9, Capvaxive |
| Boston Scientific Corporation | $160.00 | 2022-2025 | Watchman Flx |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $124.32 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.85 | 2025 | Cobenfy |
| Novartis Pharmaceuticals Corporation | $118.96 | 2020-2023 | |
| Viatris Specialty LLC | $105.82 | 2025 | Yupelri |
| Angiodynamics, INC. | $88.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $88.08 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $82.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aimmune Therapeutics, INC. | $82.35 | 2024 | |
| Kestra Medical Technology Services, INC. | $80.36 | 2024 | Assure Wcd |
| Sumitomo Pharma America, INC. | $77.46 | 2023-2025 | Gemtesa |
| Sanofi Pasteur INC. | $60.23 | 2023 | |
| Inspire Medical Systems, INC. | $51.60 | 2025 | Inspire |
| Edwards Lifesciences Corporation | $47.81 | 2025 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $42.25 | 2021 | |
| Eisai INC. | $23.48 | 2021 | |
| Ge Healthcare | $21.97 | 2019 | |
| Almatica Pharma LLC | $19.13 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.03 | 2020 | |
| Mylan Specialty L.P. | $15.02 | 2024 | Yupelri |
| Esperion Therapeutics, INC. | $12.61 | 2021 | |
| Purelife, LLC | $10.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.